Clinical trials: Melanocytoma
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Part I was a double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of LDE225 (a specific…
- Trial name
- NCT00961896
- Testing
- Vehicle, LDE225 0.25%, LDE225 0.75%
- Where
- 3 sites in Austria, Switzerland
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Melanocytic Nevi, Acquired Melanocytic Nevi
Natural History Study of Moles and Suspicious Melanoma
Background: Melanocytic nevi, or "moles," are non-cancerous growths of a type of skin cell called a melanocyte. Large congenital melanocytic nevi (LCMN) are a special type of mole that begins to grow before birth and is larger…
- Conditions
- Melanocytic Nevi, Acquired Melanocytic Nevi, Primary Cutaneous Melanoma
- Trial name
- NCT00288938
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hydatidiform Mole
A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)
This observational study aims to establish a national cohort of patients with hydatidiform mole (molar pregnancy) to investigate its malignant transformation rate and malignant transformation mechanisms, with the goal of…
- Trial name
- CN-HM-01 (NCT07202728)
- Testing
- No intervention
- Where
- 14 sites in China
- Volunteers
- 1,489 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors
RATIONALE: Learning whether temozolomide changes semen or sperm in patients with brain tumors may help doctors learn about the long-term effects of treatment and plan the best treatment.
- Conditions
- Brain and Central Nervous System Tumors, Chemotherapeutic Agent Toxicity, Infertility
- Trial name
- NCT00499798
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences
Hydatidiform Mole
RCT on the Efficacy of Methotrexate for the Prevention of GTD
A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.
- Trial name
- NCT01984099
- Testing
- Methotrexate, Vitamin B Complex
- Where
- Philippines
- Volunteers
- 99 people
- Sponsor
- University of the Philippines
Skin Carcinoma
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00783965
- Testing
- tazarotene
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- UCSF Benioff Children's Hospital Oakland
Skin Cancers - Basal Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.
This is an observational study in adult males and females utilising skin condition measurements using the LumAssure Raman device.
- Conditions
- Skin Cancers - Basal Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma, Melanoma of Skin, Inflammatory Dermatoses
- Trial name
- NCT06661577
- Where
- 2 sites in New Zealand
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Auckland, New Zealand
Hydatidiform Moles
Study of the Genetic and Epigenetic Causes of Recurrent Hydatidiform Moles
The researchers' laboratory is studying a rare class of highly recurrent hydatidiform moles. These are usually complete hydatidiform moles (CHM), but sometimes they are partial hydatidiform moles PHM).
- Trial name
- NCT01008501
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
This randomized phase III trial studies how well methotrexate works compared to dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia.
- Conditions
- Choriocarcinoma, FIGO Stage I Gestational Trophoblastic Tumor, FIGO Stage II Gestational Trophoblastic Tumor, FIGO Stage III Gestational Trophoblastic Tumor
- Trial name
- NCT01535053
- Testing
- Dactinomycin, Leucovorin Calcium, Methotrexate
- Where
- 289 sites in United States, Canada and 3 more
- Volunteers
- 57 people
- Sponsor
- GOG Foundation
Gorlin Syndrome
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use.
- Trial name
- NCT06050122
- Testing
- Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
- Where
- 40 sites in United States, France and 5 more
- Volunteers
- 113 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Hypophosphatemia, Hypophosphatemic Rickets
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
A 52 week, open label trial to assess the safety and efficacy of KRN23, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome(ENS) and associated hypophosphatemic rickets A 26 weeks…
- Conditions
- Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic
- Trial name
- NCT03581591
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Redwood Dermatology Sciences
Melanoma, Dysplastic Nevi
Family Study of Melanoma in Italy
During the course of a case-control study of melanoma conducted at the Bufalini Hospital, Cesena, Italy in the years 1994-1996, 20 families with 2 or 3 melanoma cases were identified and studied.
- Conditions
- Melanoma, Dysplastic Nevi, Melanocytic Nevi
- Trial name
- NCT00339222
- Where
- 7 sites in Italy, Spain
- Volunteers
- 1,708 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Nevus Syndrome
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
- Trial name
- NCT04308395
- Testing
- Patidegib Topical Gel, 2%
- Where
- 37 sites in United States, Belgium and 7 more
- Volunteers
- 108 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Epidermal Nevus Syndrome
A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)
KRN23 is a fully human immunoglobulin monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum phosphorus levels.
- Trial name
- ENS (NCT04320316)
- Testing
- Crysvita (burosumab-twza) Treatment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Port Wine Stain, Nevus of Ota
Optical Clearing of the Skin in Conjunction With Laser Treatments
The research hypothesis is that topical application of a mixture of pre-polymers of polypropylene glycol and polyethylene glycol (an optical clearing agent) will reduce skin light scattering, increasing the amount of light…
- Conditions
- Port Wine Stain, Nevus of Ota, Tattoos, Scars
- Trial name
- NCT00580736
- Testing
- Optical Clearing
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Ulcer, Acral Nevus
Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma.
The present clinical study aims to compare, in the two groups of patients with acral ulcers, the reparative process of the injured area, the evaluation of the healing time (with "healing" interpreted as the complete…
- Conditions
- Ulcer, Acral Nevus, Scleroderma, Digital Ulcer
- Trial name
- SUITABLE (NCT05181644)
- Testing
- EmoLED treatment, current Standard of Care
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Emoled
Nevus
Detection of Choroidal Nevus Cells in Vitrectomy Fluid
The purpose of this study is to determine if the investigators can detect the presence of choroidal nevi cells in the vitreous fluid of humans, as this may improve the diagnosis and classification of choroidal nevi and melanomas…
- Trial name
- NCT01324609
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Burosumab for CSHS
Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum…
- Trial name
- NCT03993821
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Laura Tosi
Gestational Trophoblastic Disease
Letrozole as a Prophylaxis From GTN for Complete Mole Patients
Prophylactic use of aromatase inhibitor is effective in decreasing the incidence of Gestational Trophoblastic Neoplasia (GTN) in patients with complete hydatidiform mole (CHM)
- Trial name
- NCT05203562
- Testing
- Suction evacuation, Letrozole tablets
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Zagazig University